The American Urological Association (AUA), American Society for Radiation Oncology (ASTRO), and Society of Urologic Oncology (SUO) recently announced a new clinical practice guideline for the diagnosis and treatment of advanced prostate cancer.

Findings from the first international prostate cancer quality-of-life study showed that significant numbers of men treated for the disease are struggling with continence and sexual problems after treatment. Results suggest that any treatment apart from active surveillance may negatively affect quality of life and indicate that for many men, these effects may be greater than previously thought. The findings of the Europa Uomo Patient Reported Outcomes Study (EUPROMS) were presented at the European Association of Urology (EAU) Virtual Congress.

In a study reported in the Journal of Clinical Oncology, Xie et al found that event-free survival including prostate-specific antigen biochemical failure as an event is not an adequate surrogate for overall survival in men receiving radiotherapy as primary therapy for localized prostate cancer.

Men with prostate cancer on androgen-deprivation therapy are usually treated with leuprolide, a long-acting injectable luteinizing hormone-releasing hormone (LHRH) agonist requiring an every-3-month injection, but it may be possible for ADT to be delivered by a daily oral treatment, pending regulatory approval. 

Positron-emission tomography/computed tomography (PET/CT) imaging with the prostate-specific membrane antigen (PSMA)-targeted radiotracer fluorine F-18 DCFPyL (PyL) successfully identified areas of occult metastasis in men with biochemically recurrent metastatic castration-resistant prostate cancer. This type of imaging led to management changes in about two-thirds of participants in the CONDOR trial. These results were presented at the ASCO20 Virtual Scientific Program by Michael J. Morris, MD, and colleagues.